Citigroup Inc Myovant Sciences Ltd. Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$24.03 - $27.02 $643,211 - $723,244	-26,767 Reduced 17.9%	122,752 $3.31 Million
Q3 2022 Nov 10, 2022	BUY	$11.6 - $20.44 $480,100 - $845,970	41,388 Added 38.28%	149,519 $2.69 Million
Q2 2022 Aug 10, 2022	BUY	$7.78 - $14.69 $481,457 - $909,075	61,884 Added 133.81%	108,131 $1.34 Million
Q1 2022 May 12, 2022	SELL	$11.38 - $16.4 $1.63 Million - $2.35 Million	-143,022 Reduced 75.57%	46,247 $616,000
Q4 2021 Feb 10, 2022	BUY	$14.31 - $23.87 $1.26 Million - $2.1 Million	87,812 Added 86.55%	189,269 $2.95 Million
Q3 2021 Nov 10, 2021	BUY	$18.94 - $26.99 $1.92 Million - $2.74 Million	101,457 New	101,457 $2.28 Million

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.